MedTrace Logo

IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up

NCT04242849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 354

Last updated 2025-02-21

No results posted yet for this study

Summary

In a spanish series of AML patients it is intended to perform, at the moment of diagnosis, pyrosequencing of IDH1 and IDH2 genes. Taking into account the incidence of AML in the area, it is planed to study 100 patients per year.

Among the cases with IDH1/2 mutations, targeted deep sequencing (TDS) of a panel covering coding regions of 40 myeloid related genes will be applied. With TDS, pyrosequencing results will be validated at the same time that prognosis value of co-mutated genes could be studied. Furthermore, with TDS, molecular architecture of IDH1 and IDH2 mutated cases might be better understood.

Conditions

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Josep Carreras Leukaemia Research Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2019-12-27
Completion
2020-01-16

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04242849 on ClinicalTrials.gov